

## News Release

Corona del Mar, CA --- Sept. 16, 2015



ImmunogenX™

# ImmunogenX expands its Scientific Advisory Board

## Renowned celiac disease clinicians join the SAB

ImmunogenX™ is honored to announce the addition of Professor Joseph Murray of the Mayo Clinic and Professor Peter H. R. Green of Columbia University to its Scientific Advisory Board.

Dr. Joseph A. Murray, M.D. is Professor of Medicine and Immunology and a Gastroenterologist in the Division of Gastroenterology and Hepatology at the Mayo Clinic, Rochester, Minnesota. He received his medical training in Ireland and GI training at the University of Iowa, where he founded the celiac disease clinic in 1992. He has a large clinical practice focused largely on celiac disease and runs the celiac disease research and clinical program at the Mayo Clinic. He is a senior associate editor of the American Journal of Gastroenterology as well as an expert reviewer for many scientific journals and has published over 170 scientific articles.

Dr. Peter H. R. Green is the Director of The Celiac Disease Center at Columbia University. He is a Professor of Clinical Medicine at the College of Physicians and Surgeons, Columbia University and Attending Physician at the New York-Presbyterian Hospital. Dr. Green received his medical degree from University of Sydney, Australia. After completing his Residency and GI fellowship in Sydney he became a Research fellow at Harvard Medical School and in the Gastroenterology Department at the Beth Israel Hospital in Boston. He is a Fellow of the Royal Australasian College of Physicians and the American College of Gastroenterology as well as a Member of the American Gastroenterologic Association and American Society of Gastrointestinal Endoscopy.

Dr. Jennifer Sealey-Voyksner, CTO remarks “Dr. Murray is a beacon in the field of celiacs disease and we are exceptionally fortunate to have his support for our diagnostic work. Likewise Dr. Green, a colleague of Dr. Murray’s, is a world’s leading clinician for celiacs disease treatment and research. Both individuals will lead clinical site studies of ImmunogenX’s lead diagnostic technology for monitoring intestinal health in recovering celiacs. We are ecstatic to have their expertise and commitment on board.”

## About ImmunogenX

“ImmunogenX” (a subsidiary of Immunogenics LLC) was founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors. ImmunogenX is developing new advanced diagnostic screening methods to help individuals with diagnosed celiac disease. For disease management we are extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing dietary or non-dietary treatment. This is a unique capability for which there are no other effective diagnostics. For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

[www.immunogenx.com](http://www.immunogenx.com)

## For further information please contact

Jack A. Syage, PhD  
CEO  
714 357-0631  
[jsyage@immunogenx.com](mailto:jsyage@immunogenx.com)

“ImmunogenX™”, “Immunogenics™”, “CypCel™”, and “Allergenomics™” are trademarks of Immunogenics LLC